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Abstract  
Rabies is a fatal zoonotic disease that occurs usually via animal bites. Rabies is currently an economic health 
problem in Iran and almost all of the provinces are more or less involved in this. For nearly a century, many 
researchers have tried to control rabies in Iran. To date, Iran has played a major role in the new scientific 
advances in the rabies treatment field. The Pasteur Institute of Iran was established in a 2.2 ha land to provide 
public health services for the prevention and treatment of infectious diseases. Since then, the official activity of 
the Pasteur Institute of Iran has begun. The operations of the Institute are still being developed quantitatively 
and qualitatively. The aim of this study is to introduce One-Hundred-Year Efforts by the Pasteur Institute of 
Iran as a Part of the Rabies Infectious Control Puzzle in the World. 
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1.1. Pasteur Institute of Iran: The Pasteur Institute 
was established on June 4, 1887, by Louis Pasteur 
(1822–1895) as an anti-rabies center in Paris and 
officially launched on November 14, 18881, 2. After a 
short time, the center was overcrowded, so that the 
facility could not respond to all patients. As soon as 
the Pasteur Institute was established, it attracted 
scientists with various professions2. 
In 1919, one year after the World War I (WWI), the 
Iranian government of that time tried to revive its 
scientific relations with France to enhance the status 
of medical science and research on various types of 
endemic infectious diseases in the country despite the 
fact that it was still suffering from fatalities, famines, 
and illnesses as well as the hardships resulting from 
the war3. So, Iranian political delegation traveled to 
Paris for a peace conference to reach this goal. They 
met Professor Emile Roux (Figure 1), the director of 
the Pasteur Institute of Paris in that time, in October 
19193. The meeting was the starting point of the 
establishment of the Pasteur Institute of Iran and 
Joseph Ménard (Figure 1) was nominated for the 
director of the Pasteur Institute of Iran. About three 
years after the meeting on January 20, 1921, professor 
René Legroux signed the agreement on behalf of 
Pasteur Institute of Paris with the Iranian Foreign 
Minister, which served as a model for the technical 
cooperation between the two countries3. So, the 
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Pasteur Institute of Iran was established in a 2.2 ha 
land donated by Mr. Abdol-Hossein Farman Farma 
(Figure 2) to provide public health services for the 
prevention and treatment of infectious diseases. 
Since then, the official activity of the Pasteur 
Institute of Iran has begun. The operations of the 
Institute are still being developed quantitatively and 
qualitatively3.  
2. The History  
Rabies is a fatal zoonotic disease and an 
important public health problem in the world. The 
disease is caused by neurotropic viruses in the genus 
Lyssavirus, family Rhabdoviridae (ICTV 2015)4. It is 
primarily transmitted to humans via the saliva of 
infected animals after biting. Scratching or licking of 
mucous or wounds by rabid animals is other routes 
that rabies can be transmitted5. Initially, it begins to 
replicate in the muscle at the wound site. After 
reaching the central nervous system of the host, the 
virus developed progressive encephalopathy with a 
fatal outcome5. Currently, rabies is considered as a 
neglected and emerging disease in low-income and 
developing countries6.  
Rabies has a long history, most of which have been 
lost in the distant past. Akteon, a famous mythical 
hunter, was torn to pieces by his dogs and his corpse 
was found by his entourage in the bathroom. Akteon 
seemed to be killed by a rabid dog7. The term of rabies 
is derived from the Sanskrit term rabhas. The disease 
was historically characterized by the anger of the gods, 
the spell of the witches or extraterrestrial attacks. The 
term “lisa” has been translated in English as bitten by 
a dog8. In the Dehkhoda Dictionary (Persian), rabies 
 
 
Figure 1. (A) Dr. Emile Roux (1853–1933), the director of the Pasteur Institute of Paris at the time of the Pasteur Institute of Iran 




Figure 2. (A) Pasteur Institute of Iran entrance, Tehran, Iran; (B) Mr. Abdol-Hossein Farman Farma (1852-1939). 
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has been interpreted as a crazy animal, especially 
crazy dog. 
In Iran, rabies was known to peasants and shepherds 
from ancient times. They knew that the disease is 
transmitted to humans by rabid dogs and, sometimes, 
by wolves9. Ibn Sina (980–1037 AD) (Figure 3), the 
Iranian well-known scientist, introduced the disease 
as the fear of water (hydrophobia) and recommended 
that the bitten site is not covered for 40 days and 
blistering materials are used in the wound. He has 
explicitly stated that the blood from the rabid dog is 
an antibody of its bite. This treatment method, along 
with burning the wounds was the major treatments of 
animal bites up to the early twentieth century9. In 
1885, Pasteur introduced the first weakened vaccine 
of rabies 10. Pasteur suspended the spinal cord of the 
infected rabbits in potassium-containing plate. He 
immunized some dogs by the intradermal injection of 
the suspension containing the small piece of the 
spinal cord10. The internal cytoplasmic features when 
discovered by an Italian scientist, Adelchi 
Negri (1876–1912), in 1903, became important in the 
laboratory diagnosis of rabies11. 
Up until the establishment of the rabies center in the 
Pasteur Institute of Iran, persons who were bitten by 
dogs, resorted to superstitious for the treatment and 
sometimes even lost their lives due to these activities. 
In 1923, two years after the establishment of the 
Pasteur Institute in Iran, a foreign ambassador's son 
in Tehran was injured by a suspected rabid dog and 
taken to the Pasteur Institute for treatment, while the 
institute still lacked anti-rabies services. They were 
forced to take the child out of Iran for treatment. This 
led to the decision of the authorities of the Pasteur 
Institute of Iran to establish an anti-rabies service and 
the service was launched in the institute in 1923 under 
the supervision of Dr. Mehdi Ghodsi (1900-2000). 
Gradually, other centers were established in other 
provinces and cities. According to geographic 
distributions, different animals could be a source of 
the disease. In Iran, rabies is more common in the fall 
and winter, in men than women and under 20-year-old 
subjects12.  
To date, Iran has played a major role in the new 
scientific advances in the rabies treatment field. For 
example, in 1954, Professor Marcel Baltazard (1908–
1971), the director of the Pasteur Institute of Iran and 
his assistant Dr. Ghodsi, concluded that anti-rabies 
treatment was totally valid in its used form, but not 
sufficiently effective13. The use of the vaccine 
obtained from the rabbit spinal cord continued until 
1936, and then, Dr. Ghodsi developed the anti-rabies 
vaccine by the Fermi method using the rabbit’s brain. 
Fermi vaccine was used in Iran for ten years14. Dr. 
Sabeti, the head of the vaccination center, who was in 
charge of treating the rabies-infected individuals for 
some 30 years, believed that due to the problems of 
breeding the rabbits, the Fermi anti-rabies vaccine 
could cause a nerve reaction called rabbit blow15. 
Therefore, in 1946, Dr. Ghodsi prepared the Semple 
 
 
Figure 3. Avicenna or Ibn Sina (c.980-1037) Persian polymath who’s encyclopaedia of medicine ‘The Canon of Medicine’ was the 
authoritative work on medicine throughout medieval times. 
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rabies vaccine. He observed the behavior of rabies-
infected subjects for years and followed closely the 
treatment results. In his 10-year observations, he 
found that the classic Pasteur treatment is not 
sufficient and effective in those with severe wounds 
due to the wolves’ bites and that some of those who 
were treated lost their lives due to rabies16. He 
published two shocking articles, which became a 
milestone in the history of anti-rabies treatment. The 
first article was published in 1947 in the journal of 
the Pasteur Institute of Paris and the second in 1955 
in the World Health Organization bulletin. In the two 
articles, Dr. Ghodsi evidenced the inadequacy of the 
anti-rabies vaccine when used alone for the treatment 
of rabies-infected individuals with deep and 
numerous wounds on the head and face14. 
Publication of these articles by the Iranian scientist 
made the authorities of the World Health 
Organization (WHO) aware of the defects in the 
treatment of the rabies-infected individuals. 
Consequently, the WHO Experts Committee on 
rabies decided to provide the Pasteur Institute of Iran 
not only with the rabies vaccine but also with the 
anti-rabies serum obtained by immunizing a number 
of rabbits for the treatment of subjects who were 
bitten by wolves14. The Iranian scientists at the 
Pasteur Institute sought the opportunity to treat those 
who were bitten by wolves with rabies vaccine and 
serum simultaneously. They waited four years for 
such an opportunity. In 1954, a wolf attacked 
residents in the Sahne county in the Kermanshah 
Province, wounding 29 people. The wolf was killed 
and the rabies virus was found in its brain and saliva. 
The injured subjects were transferred to the Pasteur 
Institute of Iran in Tehran for treatment. Director of 
the Pasteur Institute of Iran, Dr. Marcel Baltazar with 
Dr. Mahmoud Bahmaniyar (1919-2007) immediately 
used the anti-rabies vaccine and serum to save the 
injured subjects in two groups with the following 
methodology; the first group consisted of eighteen 
subjects with numerous and deep wounds on their 
head and face, 13 among whom received one or two 
rabies serums and a set of vaccination, and five only 
received the anti-rabies vaccine14, 15. The second 
group included eleven injured subjects with weak 
wounds away from their head and face, who were 
divided into two groups. The first group was treated 
with the serum and vaccination and the second only 
with the vaccine. The result was very significant and 
successful. From among thirteen patients treated with 
a combination of serum and vaccine, despite their deep 
wounds on the head and face, only one caught rabies 
and was died and from among the five subjects who 
were treated with the vaccine, three died. Among the 
eleven subjects of the second group who had mild 
injuries, no one caught rabies. The results of the 
treatment of the injured subjects were reported to the 
WHO Expert Committee in Geneva15. Subsequently, 
the Expert Committee suggested in 1955 that the 
combined anti-rabies serum and vaccine treatment 
method is the best way to save the rabies-infected 
subjects worldwide15. This method is used to treat 
rabies all over the world.  
In Iran, the anti-rabies serum of Heterologous was 
being produced for years by Dr. Hossein Mirshamsi 
(1917-2008) and collogues at the Razi Institute. The 
serum was highly-graded and supplied in the 
lyophilized form; however, its consumption was halted 
due to its allergic complications. Instead, the use of the 
anti-rabies serum produced in humans or anti-rabies 
immunoglobulin was made common17.  
The problem remaining in the treatment of rabies was 
complications of the vaccine produced from nerve 
tissues which occasionally led to paralysis after the 
treatment. The same problem was also observed in 
other countries of the world and was known as the 
postvaccinal paralysis. Robert Kissling (1923-2013), 
the Centers for Disease Control and Prevention 
(CDC), Atlanta, showed that the rabies virus could be 
proliferated on non-nervous cells in the in vitro 
environment for the first time18. In 1964, researchers 
from the Wistar Institute in Philadelphia successfully 
proliferated the rabies virus on the human diploid cell 
and prepared the empirical human diploid cell rabies 
vaccine (HDCV) vaccine. They proved the 
immunogenicity power and harmlessness of the 
vaccine by injecting it to 16 of their colleagues19. In 
1975, the vaccine was built on a large scale in France 
and the manufacturers successfully obtained the 
license for its use in human beings. It was then applied 
to immunize the students of the Faculty of Veterinary 
Medicine in France20. 
In 1976, the Pasteur Institute of Iran was assigned by 
the WHO to evaluate the HDCV vaccine. The Iranian 
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researchers first used this vaccine to immunize five 
volunteer groups by various methods. After 
evaluating the antibody in the volunteers, they 
considered the method of injecting the vaccine on 
days 0, 3, 7, 14, and 30 and the injection of a booster 
dose on day 90 as the best prevention treatment 
method. Researchers at the Pasteur Institute of Iran 
used the method to treat 45 subjects who were 
severely injured by two rabid wolves and six rabid 
dogs. All of these subjects were rescued from the risk 
of rabies21. At the same time, the results of their 
treatment, in addition to the results of the treatment 
of another group of rabies-infected subjects in the 
city of Essen, Germany, were examined by the WHO 
Expert Committee on rabies and was popularized 
around the world as the Essen method according to 
the recommendations of WHO22.  
In 1980, the researchers of the Pasteur Institute of 
Iran examined the immunity status of 45 patients 
treated in 1976. They took blood samples from 27 of 
the subjects before and after injecting a single dose 
of the follow up vaccine. It was determined that the 
mean antibody titer of these individuals after four 
years of treatment with the HDCV vaccine was 20.6 
IU/Serum, and after injecting a vaccine booster dose, 
the average titer reach 288 IU/Serum. The results 
showed that in people treated with HDCV vaccine, in 
case the individual is bitten again after four years, 
injection of a dose of a follow up vaccine would 
prevent rabies23,24. 
32 years after the treatment, the researchers at the 
Pasteur Institute of Iran decided to reinvestigate the 
45 rabies-infected subjects treated with HDCV 
vaccine in 1976 in terms of the strength of the rabies 
antibody inhibitor. Therefore, the researchers went to 
villages and cities where the 45 subjects were living 
32 years ago, and they could find 26 of them. The 
rabies antibody was still present in all of the subjects 
after 32 years, and when two follow up doses of the 
vaccine were injected in 3-day intervals, the antibody 
level was significantly increased. This indicated that 
those who have been treated with the HDCV vaccine 
once after animal bites could be treated with two 
doses of vaccine in a 3-day interval to prevent rabies 
if they are bitten again after 32 years24.   
During the past 40 years, due to the efforts of the 
Pasteur Institute of Iran and the Center for Reference 
and Research on rabies, Treatment and Prevention of 
rabies have undergone a number of changes to save 
lives of those bitten by rabid animals in the country. 
Problems caused by the injection of heterologous 
serum have been resolved. The neurological 
complications of brain tissues, which in some cases 
caused fatalities due to paralysis, are no longer 
observed due to the use of cell vaccines. The number 
of doses from 14 to 4 times in Zagreb regimen 
declined. Most importantly, the fatality rate of the 
treated patients has decreased significantly14. For 
example, in 1971, 1243 individuals bitten by rabid 
animals were treated and 13 were dead due to rabies. 
In 2010, however, more than 120000 bitten subjects 
received prevention-therapeutic treatments for rabies 
and the fatality rate was only 5 subjects25. 
3. The Situation of Animal Bite 
and Rabies in the World  
The virus occurs across all parts of the world except 
Antarctica (Figure 4)25. Approximately 20,000 human 
cases, which account for about one-third of annual 
rabies cases, occur in India, mostly through canine 
bites. Thus, in this country, the primary control 
measure has focused on the elimination of rabies in 
animals, mainly dogs27. People of any age are 
susceptible to rabies, but children are more at risk for 
the disease28. Although rabies is endemic in the animal 
populations in many European countries, most cases 
of rabies have been observed in Asian and African 
countries and dogs are the main carriers of the disease 
in these countries29.  
According to the investigations, in 2019, 89.7 million 
dogs and 94.2 million cats were being kept as pets in 
the US. In fact, one-third of the US population had 
pets. In this country, about 4700000 cases of animal 
biting are recorded each year, but due to the 
vaccination of pets and adequate educations, only 
about 30,000 to 50,000 cases of post-exposure 
treatment are performed30. 
In a study performed in Turkey, during 1990-2000, 
2,856 rabies cases were reported and 78% of these 
cases were reported from dogs and only 1.6% was 
from wildlife31. Most of the reported rabies cases 
during 2000 – 2010 in Azerbaijan were found in dogs, 
cattle, and sheep31. 
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4. The Situation of Animal Bite 
and Rabies in Iran 
The pet keeping trend is increasing in Iran as with 
other countries in the Middle East and Asia. About 
180000 cases of biting are observed each year in 
Iran; all of whom receive post-exposure treatments 
due to the suspicions of the pets and inadequate 
educations. Of these, about 81% of subjects are 
bitten by dogs and 69.4% of dog bites are related to 
the owned dogs32 (Figure 5).  
Rabies is currently an economic health problem in 
Iran and almost all of the provinces are more or less 
involved in this. The most cases of the disease are 
observed on the edge of the Caspian Sea, northeast 
and southwest of the country. According to the 
Ministry of Health and Medical Education, an annual 
of 160,000 individuals are treated by the Pre-
exposure prophylaxis (PrEP) measurement33. 
According to the ante-mortem diagnosis of rabies 
data of the National Center for Reference and 
Research on Rabies, the Pasteur Institute of Iran, 5-
11 individuals die from rabies in Iran annually. 
Considering that the disease is spread throughout the 
country, preventive measures must be taken in all 
provinces (Figure 6). 
5. The National Center for 
Reference and Research on 
Rabies, Pasteur Institute of Iran 
The center after establishing in 1923 was selected as 
the collaborating center by the WHO from 1973 due to 
its intensive international cooperation in the field of 
rabies. The collaboration position is renewed every 
four years, according to the terms of reference 
submitted by the department to the EMRO (Eastern 
Mediterranean Office) and by completing the WHO 
collaborating centers questionnaires. Since 2014, the 
center has obtained the national rabies authority 
certificate after implementation of ISO 15189 and as a 
collaborating center for the health reference laboratory 
of the Iran Ministry of Health and Medical Education.   
The establishment of ante-mortem rabies diagnostic 
laboratories in the country is also among the activities 
of this department. Missions of the department include 
the maintenance of scientific and technical 
achievements, the enhancement of quality and 
planning for sustainable development in the country 
 
 
Figure 4. Global distribution of rabies (WHO, 2013). No risk: there is no risk virus transmission; Low risk: pre-exposure immunization 
recommended for people who might come into contact with bats; Medium risk: pre-exposure immunization recommended for travelers 
and other people who might come into contact with bats and other wildlife; High risk: pre-exposure immunization recommended for 
travelers and other people who might come into contact with domestic animals particularly dogs and other rabies vectors31. 
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and the region. In this regard, the quantitative and 
qualitative enhancement of the bilateral, or 
multilateral, educational, research, and technical 
cooperation of the center with relevant and 
international public agencies for controlling rabies 
and aiming at its elimination are long-term missions 
of the department.  
The department is divided into five laboratories: 
5.1. Routine Rabies Diagnostic Laboratory: In the 
laboratory, the rabies-suspected brain samples of 
animals or human are investigated by the accurate 
and sensitive laboratory methods such as FAT and 
MIT and the results are sent to the center requesting 
the test in a daily manner. In this unit, the annual 
rabies statistics, including the total number of 
subjects bitten by rabid animals, rabies-related 
fatalities, the prevalence of rabies in human and 
animals in different parts of the country are discussed 
and analyzed. The Chief Executive Officer (CEO) of 
the laboratory prepares updated GIS maps on the 
prevalence of rabies. 
5.2. Serological Laboratory (Rapid Fluorescent 
Focus Inhibition Test (RFFIT)): In this laboratory, 
the anti-rabies-specific antibody assay is performed 
by the RFFIT method on human or animal sera. 
Controlling of the antibody titers in imported 
immunoglobulin sera as well as the safe domestic 
sera are performed by the experts in this laboratory. 
In addition, the Ab-rabies titer is measured by the 
ELISA method, which is a quicker method than the 
RFFIT and is used for screening. The antiviral effects 
of some medicines, as well as the virucidal effect of 
some imported or domestic disinfectant substances, 
are also examined in this laboratory.  
5.3. Laboratory for evaluating vaccines and 
biological products: In this laboratory, the potency of 
imported and domestic rabies vaccines for human and 
animal consumption is evaluated by National Institutes 
of Health (NIH) method (recommended by the WHO). 
After confirming the immunization level of the tested 
vaccines in this laboratory, based on the capabilities 
and experience of the rabies reference center and due 
to its collaboration with other relevant governmental 
organizations, such as Ministry of Health and 
Veterinary Organization, could allow the marketing of 
the vaccine in question. In the research and 
development (R&D) unit of the laboratory, research 
projects on the rabies vaccine and their immunization 
effect are being performed. 
5.4. Molecular laboratory to the diagnosis of 
rabies: In this laboratory, molecular studies and 
diagnosis on the genome of isolated strains obtained 
from all over the country are performed such as RT-
PCR, Real-Time PCR and RT-LAMP. Other 
examinations performed in the department include the 
molecular analysis of infected brain, cerebrospinal 
fluid, skin, saliva, urine, and sera samples from ante-
mortem and post-mortem rabies-suspected subjects. 
 
 
Figure 5. Comparison of the distribution of rabies in owned and stray dogs in Iran, 2000-2013 (n=1,186)30. 
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5.5. Molecular epidemiology of rabies: In this unit, 
phylogenies and phylodynamic studies are conducted 
to monitor the distribution of wild rabies strains in 
different parts of Iran. According to the latest 
publication by Dr. Nadin-Davis in 2003 and by 
sequencing of a part of the virus genome (350 bp of a 
phosphoprotein gene), it cleared that the major 
variant of the rabies virus circulating in Iran is 
cosmopolitan lineage along with a few Arctic 
variants34. In a recent cooperative study by the 
Pasteur Institute of Iran and Paris in 2017, 150 
samples were selected from different geographic 
regions and sequencing was performed for the total 
length of the viral genome. Preliminary results of this 
study indicate that circulation variant has not 
changed in comparison with Nadin-Davis study. 
Iran's Cosmopolitan variants are categorized into 
four different groups of Middle Eastern variants and 
Central Asian variants.  
6. Measures Taken so far in the 
National Center for Reference 
and Research on Rabies, 
Pasteur Institute of Iran  
6.1. Member of the National Committee of rabies 
in the Iran’s Ministry of Health and Medical 
Education (MOH): Member duty is evaluation and 
selects an anti-rabies serum and vaccine purchasing 
sources required for more than 700 rabies 
prevention-treatment centers. In addition, revisions 
and updates on the most recent therapeutic protocols 
used in this regard (according to the invitation of the 
national rabies committee of the MOH). The director 
of the center along with his experienced experts 
attends in the meetings and provides the necessary 
guideline on questions raised.  
6.2. Collaboration on drafting the National 
Vaccine Program and the use of anti-rabies safe 
serum at the MOH: Considering the annually 
increasing consumption of the biological agents in 
the prevention of rabies and according to the 
proposal of the center for the disease control of 
MOH, the center implements projects in cooperation 
with the MOH to mediate the optimum consumption 
of rabies serum and vaccine. The consumer of the 
biological agents is more than 180,000 bitten subjects 
annually. After analysis, the results of the projects will 
be proposed in national operations in the National 
Committee on Rabies.  
6.3. Collaboration on revising programs, protocols 
and identifying strategies for controlling and 
eliminating rabies in the country: The center has a 
strategic and central role in various meetings held with 
other organizations involved in this field (veterinary 
organization, environmental protection organization, 
rural and urban municipalities and ministry of health). 
It analyzes the experiences obtained by other Asian 
and European countries along with the experts from 
the French, Sri Lanka, and Pakistan to try to formulate 
a native plan for the control and elimination of rabies 
in the country. 
6.4. Collaboration on the implementation of 
educational preventive and treatment programs for 
rabies of communicable diseases Center, Iran’s 
MOH: According to the formulated educational 
programs implemented by the CDC of Iran, the 
research and reference center of rabies has actively 
participated in all educational programs in Tehran 
(Pasteur Institute of Iran) and other provinces of the 
country, explains the latest therapeutic and diagnosis 
methods for the experts in health centers or veterinary 
experts.  
7. The National Center for 
Reference and Research on 
Rabies, Pasteur Institute of Iran 
and International Centers 
Pasteur Institute is currently one of the world's leading 
research centers, with 100 research units with nearly 
2,700 employees, including fixed 500 researchers and 
600 contractual researchers, who visit some 70 
countries of the world annually. The institute also 
includes a network of 28 centers for addressing 
medical problems, specifically in the developing 
countries, all of which have a Pasteur Institute of their 
own. These 28 centers include (all in the capital of the 
country, unless another city is specified): Algeria, the 
Central African Republic, Belgium, Brazil (Sao 
Paulo), Cambodia, Senegal, France (Lille), 
Guadeloupe, French Guiana, Vietnam, Iran, Ivory 
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Coast, Madagascar, Morocco (Casablanca), New 
Caledonia, Russia (St Petersburg), Tunisia, Greece, 
Uruguay, Romania, Niger, Cameroon, South Korea, 
China (Shanghai), USA (New York), Canada 
(Montreal), Hong Kong and India (Coonoor).  
7.1. Collaboration with WHO: The center 
collaborates with WHO in different ways, including: 
1. Collecting statistical data on rabies including the 
number of subjects who bitten, the number of 
subjects who treated for rabies, the number of 
treatment cases using the vaccine alone or the 
vaccine plus serum, the type of biting animals. These 
types of data should also be prepared and submitted 
on the animal rabies. 
2. Participation in rabies control programs as a 
counselor in different counties of the region, 
including Pakistan, Afghanistan, and Yemen. 
3. Provision of the EMRO/WHO countries with the 
required guidance to control rabies. 
4. Research collaboration, especially on issues raised 
by the experts' committee, scientific groups, and 
advisory meetings.  
5. Educating the health personnel on the principles of 
anti-rabies treatment in the countries of the region. 
6. Participation in the preparation and evaluation of 
reference products.  
7. Preparation and submission of standard strains of 
rabies virus to other laboratories.  
8. Diagnosis of suspected rabies virus variants and 
evaluation of vaccines and serums from other 
laboratories. 
9. Providing advisory services on controlling rabies 
and anti-rabies treatment at the request of the WHO. 
7.2. Establishing communication bridges between 
organizations involved in controlling, treatment 
and elimination of rabies with relevant 
international centers, such as participate in the 
meetings of rabies expert in Geneva, participating 
in periodic meetings of Middle East, Eastern 
Europe, Central Asia and North 
Africa Rabies Expert Bureau (MEEREB): By the 
annual invitation of the WHO general assembly of 
experts in rabies in Geneva, the head of the 
department actively participates in these assemblies. 
He presents challenges, advances and other aspects of 
rabies control in developing countries, not only to 
advance the process of the assigned mission, but also 
to communicate information and manners with other 
centers collaborating with the WHO. In addition, 
providing this information for the relevant bodies such 






Figure 6. The species distribution of confirmed cases of animal rabies in Iran 2000-2013 (n=4,663)30. 
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8. Measures of the Pasteur 
Institute of Iran in Relation to 
Epidemiology and Control of 
Rabies in Iran  
In 1981, there was a record about 59 animal rabies 
cases that were confirmed by the Pasteur Institute of 
Iran12. In this year, a project was implemented in 
Tehran (the capital city of Iran) under the name of 
controlling rabies in stray dogs. In 1988, Tehran was 
free of rabies and the situation continued until 2000, 
by the means the disease was not observed in Tehran 
for 13 years. However, due to lack of attention and 
seriousness in the implementation of the project, a 
cat bitten an individual in Tehran was determined to 
be rabid. Based on data of the National Center for 
References and Research on Rabies, until 2003, four 
other rabid cats and a rabid cow, bitten by a rabid 
dog in the Northeastern Tehran, were found (data not 
Shown). According to statistics, animal biting is 
increasing and the most rabid animals are cows, dogs, 
sheep, wolves, monocots, equines, foxes, jackals, cats 
(Figure 6). 
As stated above, controlling rabies in stray dogs 
(1981) in Tehran or the vaccination project for dogs in 
Khorasan Province in 1994-95 caused a significant 
reduction in the percentage of rabies in these two 
provinces, but the lack of continuity of the project 
again increased the number of rabies-infected 
individuals31. Vaccination of owned and stray dogs 
plays a key role in controlling rabies. There is a 
fluctuation in controlling rabies in animals in our 
country12,31 (Figure 7). 
Considering the significant activities by the healthcare 
networks, University of Medical Sciences and CDC 
for equipping and launching the rabies-prevention 
centers, the elimination of rabies was taken seriously 
since 2015. Members of the National Committee of 
 
 
Figure 7. The distribution of rabid animals in the provinces of Iran, 2000-2013 (n=4,663)30. 
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Rabies consist of the Environment Organization 
delegation, the Veterinary Organization, the Ministry 
of the Interior, and professors from universities of 
medical sciences, the Faculty of Veterinary Medicine 
of the Universities and the Pasteur Institute of Iran. 
They decided that each of the relevant organs should 
take the rabies-elimination projects seriously in their 
own facilities, which included the following: 
Elimination of human rabies by CDC, elimination of 
rabies in domestic animals by National Veterinary, 
elimination of rabies in stray animals by 
Organization of Rural and Urban Municipalities, 
elimination of rabies in the wildlife by 
Environmental Protection Organization. 
9. Treatment and Prevention of 
Rabies in Iran 
 The animal bite has particular importance due to the 
risk of rabies in humans. In this regard, the 
community needs to be properly educated to ensure 
that it can take care of itself to prevent rabies and the 
consequences of the animal bites. In addition, by 
proper education of the dog keepers, proper measures 
should be taken in terms of vaccination of the dogs. 
The principles of the animal biting control and rabies 
in humans should be implemented by the 
coordination of other organs. In many countries, 
rabies has been completely controlled by controlling 
the disease in wildlife. Recently, international 
organizations have been focusing on vaccination of 
dogs to eliminate rabies in humans. In Iran, 
considering the tasks of each organ and the 
authorities, effective measures are in place to control 
the disease. The main aim of the national program is 
to eliminate dog-induced rabies. 
Individuals should be trained in such a way to refer 
to health centers for immediate and necessary post-
exposure prevention interventions. The National 
Center for Reference and Research on Rabies, 
Pasteur Institute of Iran holds multiple seminars with 
the help of the CDC to train the healthcare personnel 
on rabies prevention and anti-rabies treatment, 
annually.  
Disease prevention is performed by preventing the 
virus from entering the central nervous system that 
could be fatal, and it should be done under the 
supervision of a physician. The prevention process as 
follows:  
1. Training is an important point about an animal-
bitten individual and especially family members.  
2. Local washing of the wound immediately after 
exposure for 15-20 minutes; 
3. Effective rabies vaccination based on WHO 
criteria; 
4. Using anti-rabies-specific immunoglobulin when 
needed. 
Effective treatment immediately after exposure can 
prevent the emergence of clinical symptoms and 
death. Post-exposure prevention intervention is 
performed in 10-12 million children throughout the 
globe annually35.  
10. Production of Rabies Vaccine 
in the Pasteur Institute of Iran 
Diversity of susceptible host populations in wild and 
domestic animals cause the big challenge to eliminate 
the disease. Despite recent advances in technology, 
medical science and paramedics, and extensive studies 
of the last decade, unfortunately, there is still no 
treatment for the bitten individuals after the onset of 
clinical symptoms36.  
Processes of manufacturing human and animal rabies 
vaccines are similar, and the WHO has published 
standard methodologies for producing rabies vaccine. 
New generation vaccines are produced under in vitro 
conditions. In 1958, the rabies virus was adapted to 
baby hamster kidney cells (BHK) for the first time, 
and this led to significant advances in cell culturing 
techniques37. Growth of the virus in cell culture 
facilitates a large-scale production of killed or 
weakened human and animal rabies vaccine. The 
advancement of vaccine manufacturing technologies 
in the past decade has led to an increase in the 
production of adjuvanted-vaccines for animal 
immunization. Cell culture methods allow to the 
production of standard, safe, effective, economical, 
and large-scale vaccines38.  
All human rabies vaccines are a type of killed or 
inactivated viruses, but for animals, both killed and 
weakened or recombinant vaccines are produced. In 
addition, the rabies vaccines differ in terms of the 
virus strain and the cell line in which they are 
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proliferated39. The cell culture process is a suitable 
technology for large-scale production at reasonable 
prices. Various stationary systems (such as culture 
flasks) or rotary bottles and bioreactors are 
cultivation methods for propagation of suspension 
and adherent cells. Production of the vaccine on cells 
requires using of a microcarrier. This technology is 
costly for production of animal vaccines. Therefore, 
suspension cells such as BHK-21 are used for the 
animal rabies vaccines40.  
The recombinant vaccines were designed for 
immunization against several infectious agents, 
immunization against several species or strains of a 
disease or to meet both goals. One of the benefits of 
these vaccines is to reduce the frequency of 
vaccination in the immunization process against 
various diseases. In addition, these vaccines will save 
time, reduce the number of visits, maintenance costs, 
distribution, and injection of the vaccine, as well as 
make the recipients more convenient and improve the 
immunization coverage41. Of course, these types of 
vaccines also have their own disadvantages, 
including immunologic interactions and undesirable 
complications such as allergic reactions. Moreover, 
due to the possibility of biologic or chemical 
incompatibility between the substances and antigens 
in the recombinant vaccines, their vaccines cannot be 
easily produced and extensive studies and 
experiments are required41.  
Since rabies is a disease that causes the highest 
percentage of fatalities, its bio immunity has been 
one of the biggest challenges in vaccine production. 
Therefore, researchers and manufacturers of vaccines 
are aiming at production of the higher-purity, more 
efficient and cost-effective rabies vaccines42. Rabies 
virus proteins have been expressed and produced in a 
variety of microorganisms, including bacteria, yeast, 
viruses (baculovirus, herpes virus, paramyxovirus, 
and herbal viruses)43. In most cases, the rabies virus 
glycoprotein has been reported as the immunogenic 
factor in the way that it has been able to protect the 
immunized animal against the deadly dose of the 
virus during the study. However, only cases based on 
poxvirus or adenovirus have been able to take the 
complementary steps to mass production and animal 
clinical trials44  . 
The inactivated rabies vaccine is relatively 
immunogenic and commonly used in the PEP and 
PrEP measurements. The quality of the immune 
response after vaccination greatly depends on the viral 
antigens used45. Only vaccines that are pure, 
immunogenic, harmless, inexpensive and able to 
provide long-term immunity are used for the massive 
immunization of animals. Therefore, development of 
cost-effective vaccines requires choosing the right 
production processes as well as adding the adjuvant to 
the formulation, such that it does not increase the price 
of the vaccine46. Items that are different based on the 
type of the vaccine are cell line used, virus strain used, 
cell culture system, post-production processes, 
formulation methods, and the immunogenicity testing 
of the vaccine46.  
All rabies vaccines for humans contain a rabies-
inactivated virus and include the following types: 
1. Human diploid cell vaccine (HDCV): In order to 
obtain a rabies virus suspension, lack of foreign 
proteins and rabies vaccine adsorbed (RVA) the 
proteins of the central nervous system, the virus is 
cultured on the WI-38 human fibroblasts cell line. The 
virus product is concentrated by ultrafiltration and is 
then inactivated in the vicinity of beta-propiolactone47.  
2. Rabies Vaccine Adsorbed (RVA) 
3. Purified Chick Embryo Cell (PCEC) 
4. Nerve tissues vaccine: In a few cases, this vaccine 
causes sensitization of the nerve tissue and even 
encephalitis after vaccination (0.05%). 
5. Duck embryo vaccine: Duck embryo vaccine has 
been produced to minimize the post-vaccination 
encephalitis complication. In the production of this 
type of vaccine, the rabies virus grows in the duck’s 
egg. Anaphylaxis reactions are not common, but the 
antigenic potency of the vaccine is low48. 
In Iran, vaccine used for livestock has been developed 
and used for past decades on neural tissue in the 
Pasteur Institute of Iran. The brain tissue vaccine 
gradually replaced the vaccine prepared on animal cell 
culture. The rabies vaccine has been manufactured in 
Iran since 2011 with machines and industrial scale at 
the Pasteur Institute of Iran. However, human rabies 
vaccine never has not developed in Iran. The vaccine 
has been developed in the Human Rabies Vaccine 
section and the initial series has been developed with 
standards and qualities consistent with world-class 
Pharmacopeia. The vaccine has been evaluated in 
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terms of immunogenicity by measuring the survival 
rate and mortality in laboratory animals immunized 
with the vaccine. 
11. Current Status 
In addition to the increase in population, public 
awareness, as well as the number of health centers 
providing rabies prevention and treatment services, 
and increased access to these services by the 
individuals in Iran, the number of animal biting cases 
has also increased49. The highest prevalence of 
animal bites is reported in the northern provinces, for 
example, Golestan and Ardebil due to the high 
number of owned dogs31. Although there has been an 
increasing trend in animal bites during the past 28 
years (1987-2015), such that the bitten cases have 
increased from 35 in 1987 to 198 per 100000 of the 
population in 2015, the rabies cases have been 
steadily decreasing31.  
Obtaining comprehensive and reliable information on 
animal bites is difficult because most biting cases are 
small that the individual feels no necessity to refer to 
medical centers. Therefore, such cases are never 
reported to medical centers.  
In 1994, CDC performed an animal research study on 
animal bites in the US. The results showed that the 
animal biting rate was 18 per 1000 individuals per 
year. It is estimated that in the US, about 2% of the 
total population are bitten by dogs annually (five 
million people), resulting in 914 daily visits to health 
centers50. 
In Iranian wildlife, rabies is endemic and it is 
important in the natural transmission of rabies to 
dogs and domesticated animals31. In Iran, in addition 
to dogs and wild carnivores, animals such as ferrets 
can be the cause of transmission of rabies to humans. 
Therefore, bites of these animals should be 
considered as similar to other wild animal cases, and 
post–exposure therapies, i.e. anti-rabies serum and 
vaccination, should be performed31.  
According to the Zoonosis Control Department of the 
Ministry of Health, the ferret has been responsible 
for 3% rabies cases in humans in southern Iran over 
the last 10 years. In Iran, 62% of animal bites have 
been reported in rural areas and 38% in urban 
areas31.  
Although it has been a century since Louis Pasteur 
discovered the rabies vaccine, the disease is still 
endemic in most countries of the world from polar to 
tropical regions because of the diversity of susceptible 
host populations in wild and domestic animals such as 
carnivores, herbivores, rodents, and bats. Despite 
recent advances in technology, medical science and 
paramedics, and extensive studies of the last decade, 
unfortunately, there is still no treatment for the bitten 
individuals after the onset of clinical symptoms, such 
that every 10 minutes one fatality is reported due to 
rabies (more than 90% of which are in developing 
countries in Africa and India)51,52. 
Health care shortages, high prices, and the complexity 
of the production of anti-rabies vaccines often inhibit 
the prevention of human rabies in developing 
countries. Cell culture vaccines can be effective when 
the wound is properly cared for and immunoglobulin 
is used, but high costs, need for follow up doses and 
cryogenic cycles are the production problems of these 
vaccines, especially in developing countries53. 
Inactivated vaccines are currently the most commonly 
used vaccines in the world. Cell-based vaccines are 
used in developed countries where rabies is a serious 
problem. Sometimes, chemical inactivation 
deteriorates the structure of viral antigens and 
increases the risk of immunogenicity53. 
Due to the attempts made by the relevant organs in 
Iran, and by assigning the rabies prevention treatment 
facilities and raising the awareness and performance of 
the personnel of these centers as well as public 
training, the timely reference of the animal-bitten 
subjects to the prevention centers and completion of 
the vaccination course is now common. We hope that 
someday, by the proper coverage of immunization of 
the wildlife, owned and stray dogs, we can observe 
selective immunization in animal-bitten human 
subjects. 
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